Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) taking place in Orlando, Florida April 2-6, 2011. The poster presentations are based on studies utilizing Biocept's novel technology for the capture, detection, and analysis of circulating tumor cell (CTCs) in human clinical samples. This technology, Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) platform, enables not only CTC enumeration but also biomarker analysis as demonstrated in several of the posters. These data represent a broad scope of findings from studies involving blood and tumor samples from patients with breast, prostate, lung, colorectal, and ovarian cancers.

Farideh Bischoff, PhD, Director of Translational Research at Biocept, said, "In the poster presentations, data will be discussed that addresses our ability to detect CTCs that do not capture or stain with anti-EpCAM or anti-cytokeratin respectively which is the current method in the market.  Also, one of the poster presentations will cover the evaluation of HER2 gene amplification status by FISH (fluorescent in situ hybridization) in intact CTCs within a microfluidic channel.  Biocept's proprietary OncoCEE™ platform, which provides the ability to perform cytogenetic and molecular characterization of CTCs, may be an important clinically significant tool. We are excited to be developing innovative testing that may enable advances in the treatment of various cancers."  

Additional details for the AACR presentations are as follows:

Sun, Apr 3, 1:00 - 5:00 PM

319/12 - Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinoma Julie A. Mayer(1), Tam Pham(1), Karina Wong(1), Anthony Lucci(2), Farideh Bischoff(1), Savitri Krishnamurthy(2). (1)Biocept Inc., San Diego, CA; (2)The University of Texas MD Anderson Cancer Center, Houston, TX

Mon, Apr 4, 8:00 AM - 12:00 PM

1553/1 - Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs) Chad V. Pecot(1), Farideh Bischoff(2), Yvonne Lin(3), Padmavathi Jaladurgam(1), William Merritt(4), Tony Pircher(2), Steve Mikolajczyk(2), Julie Mayer(2), Karina Wong(2), Tam Pham(2), Justin Bottsford-Miller(1), Rebecca Stone(1), Joseph Celestino(1), Alpa Nick(1), Cathy Eng(1), Anil Sood(1). (1)UT M.D. Anderson Cancer Ctr., Houston, TX; (2)Biocept Incorporated, San Diego, CA; (3)University of Southern California, Los Angeles, CA; (4)South Carolina Oncology, Columbia, SC

Tue, Apr 5, 8:00 AM - 12:00 PM

LB-310/1 - FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform    

Julie A. Mayer, Tony J. Pircher, Stephen D. Mikolajczyk, Philip D. Cotter, Farideh Z. Bischoff. Biocept Inc, San Diego, CA

Wed, Apr 6, 8:00 AM - 12:00 PM

5172/13 - Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progression Stephen D. Mikolajczyk, Lisa S. Millar, Maryam Zomorrodi, Farideh Z. Bischoff, Jayne Scoggin, Tam Pham, Karina Wong, Tony J. Pircher. Biocept, Inc., San Diego, CA